BG2194U1 - COMPOSITION AND TREATMENT OF STEEL DISEASES - Google Patents

COMPOSITION AND TREATMENT OF STEEL DISEASES

Info

Publication number
BG2194U1
BG2194U1 BG003054U BG305415U BG2194U1 BG 2194 U1 BG2194 U1 BG 2194U1 BG 003054 U BG003054 U BG 003054U BG 305415 U BG305415 U BG 305415U BG 2194 U1 BG2194 U1 BG 2194U1
Authority
BG
Bulgaria
Prior art keywords
treatment
composition
product
diseases
steel
Prior art date
Application number
BG003054U
Other languages
Bulgarian (bg)
Inventor
Александър ДОЛАШКИ
Павлинка ДОЛАШКА
Мария Тодорова
Original Assignee
"Алекс 1977" Еоод
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by "Алекс 1977" Еоод filed Critical "Алекс 1977" Еоод
Priority to BG003054U priority Critical patent/BG2194U1/en
Publication of BG2194U1 publication Critical patent/BG2194U1/en

Links

Landscapes

  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Полезният модел се отнася до състав на продукт, съдържащ хидролизат от месестата част на крачето и от слузта на градински охлюв от вида Helix aspersa Muller, витамини и стабилизиращи вещества. Предлаганият продукт съдържа натурални екстракти, които не увреждат организма и спират развитието на бактериалния щам Helicobacter pylori. Предлаганият продукт може да се използва във фармацевтичната промишленост, като се влага във фармацевтичен препарат за лечение на болести на стомаха и дванадесетопръстника. 1 претенция, 2 фигуриThe useful model refers to the composition of a product comprising a hydrolyzate from the flesh of the foot and the mucus of a snail of the species Helix aspersa Muller, vitamins and stabilizers. The product offered contains natural extracts that do not damage the body and stop the development of the bacterial strain Helicobacter pylori. The product may be used in the pharmaceutical industry by incorporating it into a pharmaceutical preparation for the treatment of gastric and duodenal diseases. 1 claim, 2 figures

BG003054U 2015-07-16 2015-07-16 COMPOSITION AND TREATMENT OF STEEL DISEASES BG2194U1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BG003054U BG2194U1 (en) 2015-07-16 2015-07-16 COMPOSITION AND TREATMENT OF STEEL DISEASES

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BG003054U BG2194U1 (en) 2015-07-16 2015-07-16 COMPOSITION AND TREATMENT OF STEEL DISEASES

Publications (1)

Publication Number Publication Date
BG2194U1 true BG2194U1 (en) 2016-03-31

Family

ID=56801957

Family Applications (1)

Application Number Title Priority Date Filing Date
BG003054U BG2194U1 (en) 2015-07-16 2015-07-16 COMPOSITION AND TREATMENT OF STEEL DISEASES

Country Status (1)

Country Link
BG (1) BG2194U1 (en)

Similar Documents

Publication Publication Date Title
MX2018014083A (en) Nutritional compositions for cardciac protection in companion animals.
PE20180523A1 (en) CO-AGONIST COMPOUNDS OF GLUCACON AND GLUGACON-SIMILAR PEPTIDE-1 (GLP-1)
JOP20190146A1 (en) Amino acid compositions and methods for the treatment of liver diseases
MX2019001903A (en) Compositions and methods for modulating gastrointestinal microflora in a canine.
MX2019006864A (en) Treatment of a disease of the gastrointestinal tract with a tnf inhibitor.
JOP20190147A1 (en) Amino acid compositions and methods for the treatment of muscle diseases and disorders
PH12017500032A1 (en) Improved a� protofibril binding antibodies
BR112016024352A2 (en) "recombinant listeria strain, recombinant listeria, pharmaceutical composition, and methods of inducing an immune response against a tumor or cancer in a human and listeria individual"
EA201890223A1 (en) LACTOBACILLUS PARACASEI FOR THE PRODUCTION OF LINECOIC ACID, WITH CONNECTED LINKS, NUTRITIONAL AND PHARMACEUTICAL PREPARATIONS CONTAINING THIS STRAIN, AND THEIR APPLICATION
JOP20200033A1 (en) Amino acid compositions for the treatment of liver disease
SG10201809701TA (en) Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent
MX2017002584A (en) Composition and medicinal product for reducing body weight and body fat, and use of said product.
EA201691436A1 (en) COMPOSITION INCLUDING OKRA TO BE USED IN REDUCING THE ABSORPTION OF FOOD FAT
MX2019003703A (en) Safe and effective method of treating psoriasis with anti-il23 specific antibody.
MX2018008793A (en) Pharmaceutical or nutritional combination comprising beta-hydroxy-betamethylbutyrate.
PH12019500377A1 (en) Composition comprising multivalent capsular polysaccharide-transport protein and use thereof
MX2017004662A (en) Compositions and methods for enhancing mobility or activity or treating frailty.
MX2022002635A (en) Angiopoietin-like 4 antibodies and methods of use.
MX2019010707A (en) Methods of treating and/or preventing actinic keratosis.
MX2017003217A (en) Treatment of cancer with alpha-amylase inhibitor in companion animals.
MX2022004382A (en) Methods of promoting scfa production by gut microbiota.
BG2194U1 (en) COMPOSITION AND TREATMENT OF STEEL DISEASES
IN2014DN09240A (en)
WO2015200768A3 (en) Pharmacologic treatments of menière's disease
RU2014154366A (en) APPLICATION OF THE PROBIOTIC STRAIN OF THE MICROOORGANISM ENTEROCOCCUS FAECIUM L3 FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES